PBC Surveillance Schedule
All patients with PBC should undergo annual symptom assessment (fatigue and pruritus), biochemical monitoring after 1 year of UDCA therapy for risk stratification, and osteoporosis screening at least every 5 years, with additional surveillance for hepatocellular carcinoma and varices based on disease stage. 1
Core Surveillance Components
Biochemical Monitoring and Treatment Response Assessment
- Perform risk stratification using biochemical response indices at 1 year after initiating UDCA therapy to identify patients at risk for progressive disease 1
- This 1-year assessment is critical for determining whether second-line therapy is needed
- After the first year, continue regular biochemical monitoring (ALP, bilirubin, liver enzymes) though specific intervals are not rigidly defined in the guidelines 2
- Patients with specialist care (hepatology/gastroenterology) demonstrate significantly higher adherence to monitoring (65-78% vs 30-57% without specialist care) 2
Annual Symptom Evaluation
Document presence or absence of fatigue and pruritus at least annually (90% standard target) 1
This is not merely documentation—these symptoms profoundly impact quality of life and require active management:
- Fatigue is the symptom with the biggest impact on patients and correlates with emotional distress 1
- Systematic symptom assessment ensures timely intervention and prevents deterioration in quality of life
Osteoporosis Surveillance
Perform osteoporosis risk assessment at least every 5 years (80% standard target) 1
- This addresses the significant risk of osteoporotic fractures in PBC patients
- Treatment and follow-up should follow national osteoporosis guidelines
- More frequent monitoring may be warranted in high-risk patients (postmenopausal women, those on corticosteroids)
Disease Progression Monitoring
Patients with bilirubin >50 μmol/L or any evidence of decompensated liver disease require immediate hepatologist referral for transplant evaluation 1
This threshold is critical for mortality reduction—delays in transplant referral directly impact survival.
Baseline and Periodic Imaging
- Abdominal ultrasound at baseline to exclude alternative causes of cholestasis (90% standard) 1
- For patients with cirrhosis or advanced fibrosis, implement standard hepatocellular carcinoma surveillance (ultrasound ± AFP every 6 months) and variceal screening per standard cirrhosis protocols
Common Pitfalls to Avoid
Failing to reassess at 1 year post-UDCA: This is when treatment response should be formally evaluated using validated scoring systems (GLOBE or UK-PBC scores). Missing this window delays identification of inadequate responders who need second-line therapy 3, 4
Inadequate biochemical monitoring frequency: Studies show only 52-67% adherence to recommended monitoring in routine practice 2. Establish systematic recall systems.
Neglecting symptom assessment: 90% of patients should have documented symptom evaluation annually, yet this is often overlooked 1. Fatigue and pruritus severely impact quality of life even when liver biochemistry appears stable.
Delayed osteoporosis screening: The 5-year interval is a minimum—don't wait longer, as fracture risk is substantially elevated in PBC.
Risk-Stratified Approach
The surveillance intensity should increase based on:
- Biochemical response to UDCA at 1 year: Non-responders need closer monitoring and consideration of second-line agents
- Fibrosis stage: Advanced fibrosis/cirrhosis requires HCC surveillance and variceal screening
- Bilirubin elevation: Values >50 μmol/L trigger transplant evaluation pathway
- Symptom burden: Severe pruritus or fatigue may require more frequent visits for symptom management optimization
The BSG/UK-PBC guidelines 1 emphasize that these service standards represent minimum targets for quality care, with the explicit goal of reducing morbidity and mortality through systematic surveillance and early intervention.